Sensitive Nanozyme Test May Provide Rapid Point-of-Care Diagnosis of Ebola
|
By LabMedica International staff writers Posted on 24 Sep 2015 |

Image: In the new nanozyme immunochromatographic strip test for Ebolavirus (EBOV), the magnetic (A) and catalytic (B) properties of the nanozymes (Fe3O4 magnetic nanoparticles (MNPs)) make the signal 100 times stronger than standard strips with colloidal-gold nanoparticles, generating a deeper color reaction that can be more clearly seen by the naked eye (Image courtesy of Duan D et al., 2015, and Elsevier).
Researchers have developed a simple low-cost Ebolavirus (EBOV) test based on detection technology using magnetic nanoparticles that has shown 100x higher sensitivity than the standard immunochromatographic ELISA gold strip test.
In a new study led by Xiyun Yan, professor at the Institute of Biophysics, Chinese Academy of Sciences (Beijing, China), a nanozyme strip test was developed that is similar to the gold strip test but instead uses Fe3O4 magnetic nanoparticles (nanozymes) that enhance the signal via their intrinsic enzyme-like activity. Results showed 100x higher sensitivity than the gold strip test—the new test detects EBOV glycoprotein at concentrations as low as 1 nanogram/mL. Also, to concentrate the virus particles in the sample, the tube bottom is simply held against a magnet, so no expensive lab equipment is needed.
Early accurate detection is a key to controlling the Ebola outbreak as patients can then be isolated and treated. Current tests are either too expensive to be useful where they are most needed, or not sensitive enough to provide accurate diagnosis. PCR testing is highly sensitive but expensive and complicated, requiring specialized skills and equipment. Testing with the ELISA gold strip is inexpensive, but sensitivity is low.
“Our new strip test is a simple, one-step test that is cheap and easy to use, and provides a visible signal, which means people don’t need training to use it. We think it will be especially helpful in rural areas,” said Prof. Yan, “We’re very excited about our new nanozyme test, as it is much more sensitive and you don’t need any specialist equipment to get a quick, accurate result.” Her colleagues at the Chinese Center for Disease Control and Prevention (CDC) will field-test it in West Africa for its EBOV diagnostic and screening potential. The researchers are also developing automatic equipment to reduce risk of test contamination from hand-contact.
The nanozyme test is the result of an interdisciplinary collaboration of scientists and clinicians. The researchers are collaborating to develop this robust technology further as it can be applied for detection of other biological molecules, making it useful to diagnose additional infectious diseases and to potentially detect cancer tumors. It is also being tested for its potential to help in decontamination for wastewater treatment.
“We had an idea and talked to many people about it, and the result is a test that will overcome a problem,” said Prof. Yan, “We have built strong collaborations that have finally made this method successful, and we’re looking forward to applying it to many other areas.”
The study, by Duan D et al., was published online ahead of print 11 May 2015, in the journal Biosensors and Bioelectronics.
Related Links:
Chinese Academy of Sciences
Elsevier
In a new study led by Xiyun Yan, professor at the Institute of Biophysics, Chinese Academy of Sciences (Beijing, China), a nanozyme strip test was developed that is similar to the gold strip test but instead uses Fe3O4 magnetic nanoparticles (nanozymes) that enhance the signal via their intrinsic enzyme-like activity. Results showed 100x higher sensitivity than the gold strip test—the new test detects EBOV glycoprotein at concentrations as low as 1 nanogram/mL. Also, to concentrate the virus particles in the sample, the tube bottom is simply held against a magnet, so no expensive lab equipment is needed.
Early accurate detection is a key to controlling the Ebola outbreak as patients can then be isolated and treated. Current tests are either too expensive to be useful where they are most needed, or not sensitive enough to provide accurate diagnosis. PCR testing is highly sensitive but expensive and complicated, requiring specialized skills and equipment. Testing with the ELISA gold strip is inexpensive, but sensitivity is low.
“Our new strip test is a simple, one-step test that is cheap and easy to use, and provides a visible signal, which means people don’t need training to use it. We think it will be especially helpful in rural areas,” said Prof. Yan, “We’re very excited about our new nanozyme test, as it is much more sensitive and you don’t need any specialist equipment to get a quick, accurate result.” Her colleagues at the Chinese Center for Disease Control and Prevention (CDC) will field-test it in West Africa for its EBOV diagnostic and screening potential. The researchers are also developing automatic equipment to reduce risk of test contamination from hand-contact.
The nanozyme test is the result of an interdisciplinary collaboration of scientists and clinicians. The researchers are collaborating to develop this robust technology further as it can be applied for detection of other biological molecules, making it useful to diagnose additional infectious diseases and to potentially detect cancer tumors. It is also being tested for its potential to help in decontamination for wastewater treatment.
“We had an idea and talked to many people about it, and the result is a test that will overcome a problem,” said Prof. Yan, “We have built strong collaborations that have finally made this method successful, and we’re looking forward to applying it to many other areas.”
The study, by Duan D et al., was published online ahead of print 11 May 2015, in the journal Biosensors and Bioelectronics.
Related Links:
Chinese Academy of Sciences
Elsevier
Latest Microbiology News
- Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
- Label-Free Microscopy Method Enables Faster, Quantitative Detection of Malaria
- Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
- Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
- Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
- Antibiotic Resistance Genes Found in Newborns Within Hours of Birth
- Rapid Color Test Stratifies Virulent and Resistant Staph Strains
- mNGS CSF Test Identifies CNS Pathogens Missed by Standard Panels
- Syndromic Panel Enables Rapid Identification of Bloodstream Infections
- RNA-Based Workflow Identifies Active Skin Microbes for Dermatology Research
- Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
- New Bacterial Target Identified for Early Detection of Noma
- Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
- Rapid Urine Test Speeds Antibiotic Selection for UTIs
- WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
- Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
Channels
Clinical Chemistry
view channel
Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders
Delays in diagnosing serious psychiatric conditions can leave patients without timely support and complicate treatment planning. For bipolar disorder, average time to diagnosis can exceed nine years, and... Read moreAt-Home Blood and Cognitive Tests Support Dementia Risk Stratification
Dementia places a substantial burden on patients and health systems, and identifying individuals at elevated risk remains difficult at scale. In the UK, almost a million people are estimated to be living... Read moreMolecular Diagnostics
view channel
Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about 30% of people worldwide and can advance to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and... Read more
Patented Isothermal Amplification Chemistry Advances Decentralized Testing
Molecular diagnostics offer high sensitivity for pathogen detection but typically rely on thermal cycling and specialized instruments, limiting their use outside centralized laboratories.... Read more
Finger-Prick Blood Test Aids Early Tuberculosis Detection and Risk Stratification
Household contacts of people with tuberculosis face an estimated 2% risk of developing disease, yet most are asymptomatic at the time of screening. Early-stage cases are often missed because symptom checks... Read more
Urine Test Beats MRI in Identifying Prostate Cancer Upgrading During Active Surveillance
Active surveillance is common for men with low-risk prostate cancer, yet deciding when to repeat biopsy remains challenging. Prostate-specific antigen (PSA) testing and magnetic resonance imaging (MRI)... Read moreHematology
view channel
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read moreImmunology
view channel
Biomarkers and Molecular Testing Advance Precision Allergy Care
Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read more
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
Latent tuberculosis remains a substantial testing workload for clinical laboratories as screening programs expand. Despite this growth, only about 40% of testing has shifted from traditional skin tests... Read more
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more








